Navigation Links
Origen publishes in Nature a robust and versatile method for creating transgenic chickens

Origen Therapeutics announced today that it has succeeded in developing a robust and versatile technology for genetically modifying chickens that, for the first time, puts avian transgenics on a par with transgenic mice. The company made the announcement in conjunction with the publication of an article this week by Origen scientists and a collaborator from the University of California, Davis on its transgenic technology in the journal Nature.

Using the new technology, Origen can, in principle, make any genetic modification desired to the chicken genome, including the insertion of genetic elements for the production of human therapeutics and the modification of the chicken immune system to produce novel human sequence polyclonal antibodies. Moreover, the new technology opens up the possibility of producing chickens with enhanced agronomic traits, including resistance to avian flu.

"This research breakthrough came when we turned our attention to primordial germ cells, the precursor cells to sperm and eggs," said Marie-Cecile van de Lavoir, senior scientist at Origen. "These cells ?which we are the first to successfully culture without changing their commitment -- proved to be the key to introducing genetic elements into the chicken genome. As a result, we can now take transgene designs that work well in model systems and breed flocks of birds depositing therapeutic proteins in their eggs. The use of primordial germ cells, the ease of producing small or large flocks of chickens, and the existing infrastructure for rearing chickens and processing eggs means that therapeutic proteins can now be produced efficiently and economically in the eggs of chickens."

Origen scientists first demonstrated the potential for the production of human protein therapeutics in chicken eggs in August 2005, when company scientists published in Nature Biotechnology the production of human sequence monoclonal antibodies having greatly enhanced cancer killing activity co mpared to antibodies produced via conventional methods.

"While that earlier research was done with chimeric chickens, it demonstrated the enormous opportunities that transgenic chickens hold as a therapeutics production system," said Robert Kay, Ph.D. Origen Therapeutics president and chief executive officer. "We believe a transgenic chicken system offers a number of advantages over either plant or other transgenic animal systems for protein production. Besides the ability to produce antibodies with enhanced cell killing properties, the time from antibody identification to production in eggs is a matter of months, the purification of proteins from eggs is relatively simple, and good manufacturing practices have long been established for vaccine production in chicken eggs. Moreover, the overall cost of facility and operations is a fraction of that associated with fermentation methods of manufacture. The ability to readily create transgenic chickens through this technology, and then to scale up production through conventional breeding further adds to the practicality of this technology for large-scale production of therapeutic proteins."

In the early embryo, only a few cells known as primordial germ cells (PGCs) become sperm or eggs in the adult animal. Previous attempts to culture PGCs from mice and humans produced embryonic germ cells that look and act like embryonic stem cells. The chicken is the first species from which PGCs can be isolated, cultured and genetically modified while retaining their commitment to the germ line. Additionally, under certain conditions, Origen scientists could induce the PGCs in vitro to differentiate into embryonic germ cells that contribute to somatic tissue.

"As well as the practical applications of this work, the ability to engineer PGCs and influence them to commit in cell culture to either the germline or the somatic lineages provides a very useful new tool for understanding some of the earliest and most fu ndamental events in developmental biology on a molecular level," said Robert J. Etches, Ph.D., D.Sc., vice president of research at Origen Therapeutics.

"This work addresses a major biomedical issue -- how to produce antibody-based medicines in an easy, cost-effective way," said Matthew E. Portnoy, Ph.D., of the National Institute of General Medical Sciences, which partially funded the research. "Beyond that, it will help researchers understand stem cell biology and development --something that holds great value for all sorts of basic studies. This is exactly the kind of result we hope for through our Small Business Innovation Research Program."


'"/>

Source:jkureczka@comcast.net


Related biology news :

1. PLoS Medicine publishes first trial of effect of male circumcision on HIV infection
2. DOE publishes research roadmap for developing cleaner fuels
3. Nature provides inspiration for important new adhesive
4. First production of human monoclonal antibodies in chicken eggs published in Nature Biotechnology
5. Rewind, please: Nature paper shows that cell division is reversible
6. Natures process for nitrogen fixation caught in action
7. Towards precise classification of cancers based on robust gene functional expression profiles
8. Spleen may be source of versatile stem cells
9. Anemone genes reveal versatile building blocks for body plans
10. Engineer ramps up protein production, develops versatile viral spheres
11. Color-blind method opens new doors in DNA sequencing
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... 2016 Perimeter Surveillance & Detection ... Physical Infrastructure, Support & Other Service  The ... offers comprehensive analysis of the global Border Security ... revenues of $17.98 billion in 2016. Now: ... leader in software and hardware technologies for advanced video ...
Breaking Biology News(10 mins):
(Date:6/22/2016)... Washington, USA (PRWEB) , ... June 21, 2016 , ... ... and without cutting into the tissue — promise to enable both compact, wearable devices ... and from even deeper under the skin. , Recent work and visionary future directions ...
(Date:6/22/2016)...  Mesa Biotech Inc., a privately-held, molecular diagnostic ... specifically for point-of-care (POC) infectious disease diagnosis, today ... (SAB). Approved by the executive leadership team and ... advise on the development and commercialization of Mesa ... Steve Young , this world-class team brings ...
(Date:6/22/2016)... 22, 2016 On Tuesday, June 21, ... up 0.14%; the Dow Jones Industrial Average advanced 0.14% to ... up 0.27%. The gains were broad based as five out ... initiated coverage on the following equities: Minerva Neurosciences Inc. (NASDAQ: ... PTLA ), Trevena Inc. (NASDAQ: TRVN ), and ...
(Date:6/21/2016)... (PRWEB) , ... June 21, 2016 , ... Three young ... diseases and explore the depths of space with today’s announcement of the winners of ... Awards, given annually by the Blavatnik Family Foundation and administered by the New ...
Breaking Biology Technology: